RYR2 and AL amyloidosis: Inhibition of CT-like activity with ixazomib (IXA), a proteasome inhibitor currently used in patients with multiple myeloma [7], prevents RyR2 degradation during ischemia and significantly improves cell survival after ischemia/reperfusion [6].